1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Job cuts at Antisense Pharma as lead candidate hits side-effect problem in glioma

 
• By Sukaina Virji

Antisense Pharma of Germany is likely feeling mighty relieved that it was forced to terminate the Phase III SAPPHIRE trial of its lead product trabedersen last year. While the original decision was taken because of a lack of eligible patients, preliminary analysis of data from the 27 patients that did participate has just revealed that local administration of trabedersen, a TGF-β2 inhibitor, led to certain serious adverse events (SAE). The company declined to provide further details on the SAEs, but final data will be available in the third quarter.

Antisense Pharma of Germany is likely feeling mighty relieved that it was forced to terminate the Phase III SAPPHIRE trial of its lead product trabedersen last year. While the original decision was taken because of a lack of eligible patients, preliminary analysis of data from the 27 patients that did participate has just revealed that local administration of trabedersen, a TGF-β2 inhibitor, led to certain serious adverse events (SAE). The company declined to provide further details on the SAEs, but final data will be available in the third quarter.

According to the company: "The convention-enhanced delivery of trabedersen via intra-cranial infusion with surgical catheter placement seemed to result in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 
• By Andrew McConaghie

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.

More from Therapeutic Category

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 
• By Sushmita Panda

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.